Investment firm Raymond James increased its price target for Rapport Therapeutics (NASDAQ: RAPP) to $86.00, reflecting strong analyst confidence in the biopharmaceutical company. The upward revision follows positive Phase 2 clinical trial results for its lead candidate, RAP-219, in treating acute…
H.C. Wainwright maintained a Buy rating for Rapport Therapeutics and significantly raised its price target from $40.00 to $66.00. Rapport Therapeutics' lead drug candidate, RAP-219, showed positive Phase 2 trial results for acute bipolar mania, meeting its primary endpoint. Analysts estimate…
Every article on every company, fresh through the day, plus search for any ticker. Pop in your email to unlock it.
You'll get Gro's newsletter too. Leave any time in one click.
Articles from Financial Modeling Prep.
